Search results
Results from the WOW.Com Content Network
Antidepressant discontinuation syndrome, also called antidepressant withdrawal syndrome, is a condition that can occur following the interruption, reduction, or discontinuation of antidepressant medication following its continuous use of at least a month. [5]
A drug holiday (sometimes also called a drug vacation, medication vacation, structured treatment interruption, tolerance break, treatment break or strategic treatment interruption) is when a patient stops taking a medication(s) for a period of time; anywhere from a few days to many months or even years if the doctor or medical provider feels it is best for the patient.
Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor. [7]
The symptoms from withdrawal may be even more dramatic when the drug has masked prolonged malnutrition, disease, chronic pain, infections (common in intravenous drug use), or sleep deprivation, conditions that drug abusers often develop as a secondary consequence of the drug. When the drug is removed, these conditions may resurface and be ...
Ticagrelor was the first reversible inhibitor of the P2Y 12 receptor, active after oral administration. Ticagrelor is orally active without the need for any metabolic activation. It is rapidly absorbed and undergoes enzymatic degradation to at least one active metabolite which is almost as potent as its parent compound. Ticagrelor has improved ...
After five nights, the remaining subjects were allowed to sleep undisturbed, and showed a significant increase in percentage of sleep devoted to REM: from an average of 19.4% to an average of 26.6%. These effects were significant in comparison with a control group woken up on an equal number of occasions each night, at arbitrary times.
Ticagrelor (Brilinta) is often listed with thienopyridine inhibitors and has similar indications for use but is not a thienopyridine. It is a cyclo-pentyltriazolo-pyrimidine that is distinct from the mechanism of the thienopyridines in that it reversibly (rather than irreversibly) inhibits the P2Y 12 receptor.
A meta-analysis found cognitive impairments in many areas due to benzodiazepine use show improvements after six months of withdrawal, but significant impairments in most areas may be permanent or may require more than six months to reverse. [128] Protracted symptoms continue to fade over a period of many months or several years.